WHO INN approves ‘Usnoflast’ as recommended name for ZYIL1 from Zydus
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus. Studies have demonstrated that ZYIL1 is…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Amyotrophic Lateral Sclerosis
Coya, Dr Reddy’s sign pact to develop and market COYA 302 for treatment of ALS
Coya retains the right to commercialise COYA 302 for patients with amyotrophic lateral sclerosis (ALS) in Japan, Mexico, and each…
Zydus begins Phase II trial of ZYIL1, NLRP3 inhibitor in patients with ALS
USFDA has granted Zydus an ‘Orphan Drug Designation’ for ZYIL1 to treat patients with Cryopyrin Associated Periodic Syndrome…
Global ALS market may grow to $1.04 bn in 2029 driven by anticipated drug launches
A GlobalData report also informs that there are major unmet needs in the ALS market, such as finding curative drugs, receiving…
IIT Hyderabad researchers find new molecule to potentially treat Amyotrophic Lateral Sclerosis
ALS is a neurodegenerative disorder that severely affects the voluntary movement of the muscles and can lead to paralysis and…